Daniel Swerdlow

[Office for Translational Research, SCM, UoC @OTR_Cambridge]

Thank you to Mark Edbrooke, @DanielSwerdlow, @DrCathyWilson and Peter Oliver for your insightful talks at yesterday's #CamNTF event! Your expertise in nucleic acid therapeutics is truly inspiring. #Grateful #FutureOfHealthcare

[theproductcompound @productcompound]

We’re hosting our first meetup for Product People and those involved in early R&D in pharma/biotech on June 18th in London Kings Cross.

Come down and contribute to the discussion on how Product can bring value to the drug development pipeline!
🚀
https://t.co/5cHWnZ6UO2

[Daniel Swerdlow @DanielSwerdlow]

Drug discovery people in pharma and biotech - here's something for you: @productcompound Come and learn what product people and product mindset can bring to the work we do https://t.co/7VMPU3a1rI https://t.co/Ru6HqjwZ1N

[Daniel Swerdlow @DanielSwerdlow]

Calling #oligonucleotide therapeutics folks - please submit topics you would like to see on the agenda at the DIA oligo-based therapeutics meeting in Oct 2024 - we're putting the meeting together now and it's going to be a good one! https://t.co/fopTgKfvzh #Oligo24

[Wave Life Sciences @WaveLifeSci]

Yesterday we announced the initiation of dosing in healthy volunteers in the RestorAATion clinical trial program, which is investigating WVE-006 for #AATD. WVE-006 is the first #RNAediting candidate ever to be evaluated in the humans. Click below to read more. $WVE

[Daniel Swerdlow @DanielSwerdlow]

@AH_AlbertHenry Bravo Albert!! Fantastic news and very well deserved

[Craig Glastonbury @C_Glastonbury]

Come and join my group in Milan! Five year research position. Open to multiple profiles. Machine learning researchers interested in large-scale imaging, genetics and health-research apply! Attractive 90% tax exemption for people new or returning to Italy.
https://t.co/Fa15a75Hen

[Daniel Swerdlow @DanielSwerdlow]

Great to be back at #EASCongress2022 in person in Milan. Looking forward to a stimulating three days @SilenceTheraPlc @society_eas

[JAMA @JAMA_current]

In a phase 1 study of participants with elevated Lp(a) levels and no known cardiovascular disease, the siRNA SLN360 was well tolerated, and a dose-dependent lowering of plasma Lp(a) concentrations was observed. https://t.co/1xFn46qFum #ACC22

[Amit V. Khera @amitvkhera]

Lipoprotein(a) has been deemed important but inactionable for years. In addition to other meds in development, new data from ⁦@SilenceTheraPlc⁩ siRNA at #ACC22 in healthy participants with increased lipoprotein(a) notes suppression up to 98%! ⁦@TheFHFoundation⁩

[Silence Therapeutics @SilenceTheraPlc]

Attention #ACC22 early birds! Our APOLLO phase 1 #Lpa data will be presented this morning at 8:45 ET, during the JAMA Late-Breaking Clinical Trials session. Grab a coffee and tune in. #SilenceIsGOLDen

[Maciej Banach @maciejbanach]

The #lipid lowering world is changing before our eyes! #siRNA in the hyperLPA #therapy. Looking forward to seeing the results of the APOLLO trial. @SilenceTheraPlc @rblument1 @drpablocorral @cpcannon @Lpa_Doc @pabeda1 @VietHeartPA @DrMarthaGulati @FeliceGragnano @MeralKayikcoglu

[Silence Therapeutics @SilenceTheraPlc]

Tomorrow, Dr. Steven E. Nissen of the @ClevelandClinic will be presenting the phase 1 APOLLO Trial data for our investigational siRNA therapy for high #Lpa. Get up to speed on the science: https://t.co/3SrDSjidzC #SilenceIsGOLDen

[Silence Therapeutics @SilenceTheraPlc]

Today is the first ever #LpaAwarenessDay. We’re grateful to have met many members of this disease community through our Lp(a) clinical program. We are committed to using our gene-silencing science to better serve your needs: https://t.co/dJcbYzT4Pt

[World Heart Federation @worldheartfed]

Today is #LpaAwarenessDay. Lipoprotein (a) is an inherited condition that affects 1 in 5 people and increases your risk of cardiovascular disease.

Talk to your doctor about testing for Lp(a) and how to reduce other #CVD 💔 risk factors.

https://t.co/KqBxTQ0Oe4 #KnowLpa

[Daniel Swerdlow @DanielSwerdlow]

Great to see a showcase of the UK as an AI powerhouse at @FoundSciTech #fstAI. Proud that @SilenceTheraPlc is putting AI/ML into action for siRNA drug discovery and development

[Silence Therapeutics @SilenceTheraPlc]

#ICYMI: $SLN announced positive phase 1 data of our #genesilencing treatment, which aims to address the unmet need of those living with high levels of #Lipoproteina. Learn more at our late-breaking #ACC22 presentation: https://t.co/frw8fOJzxg #SilenceisGOLDen

[Daniel Swerdlow @DanielSwerdlow]

Fantastic news!! #sirna #lpa

[Silence Therapeutics @SilenceTheraPlc]

We are excited to announce positive Phase 1 data of our gene silencing therapy, which aims to silence Lipoproteina (#Lpa), a risk factor for #heartdisease. Read more here: https://t.co/54GZ9qgn0f #SilenceisGOLDen #AmericanHeartMonth #biotech $SLN

[Endpoints News @endpts]

In a small study released Wednesday, Silence Therapeutics showed that at a high dose, its RNAi technology could reduce a patient’s lp(a) levels by 98%.

https://t.co/4usJEOJHcL